Axogen (AXGN) vs InMode (INMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen (AXGN) has outperformed InMode (INMD) over the past year, gaining 110.8% versus a loss of 6.4%. Over five years, AXGN leads with a +165.6% price change compared with -83.1% for INMD. Axogen is the larger company by market cap ($2.12 billion vs $810.2 million), about 2.6 times the size.
On valuation, InMode trades at a lower forward P/E (10.3x vs 52.6x for Axogen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | INMD |
|---|---|---|
| Share price | $36.18 | $14.08 |
| Market cap | $2.12B | $810.22M |
| 1-day change | +0.39% | +0.50% |
| YTD return | +10.54% | -4.15% |
| 1-year return | +110.84% | -6.45% |
| 5-year return | +165.64% | -83.11% |
| P/E ratio (TTM) | — | 11.64 |
| Forward P/E | 52.59 | 10.26 |
| EPS (TTM) | $-0.67 | $1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | — |
| Revenue growth (YoY) | +20.21% | — |
| Net income (latest FY) | $-15.70M | — |
| Gross margin | 74.31% | — |
| Operating margin | -3.49% | — |
| Net margin | -6.97% | — |
| 52-week high | $52.91 | $16.67 |
| 52-week low | $15.27 | $12.72 |
| Distance from 52-week high | -31.62% | -15.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +48.76% | +14.84% |
| Average volume | 1.22M | 501.37K |
| Shares outstanding | 58.67M | 57.54M |
| Employees | 622 | 660 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 2.6 times larger than InMode by market value ($2.12B vs $810.22M).
- AXGN has outperformed INMD by 117.3 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
AXGN vs INMD FAQ
Which is bigger, Axogen or InMode?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $810.22M for InMode (INMD).
Which stock has performed better over the past year, AXGN or INMD?
AXGN returned +110.84% over the past 12 months, compared with -6.45% for INMD (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and InMode in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.